Answers are grounded in this paper and cite their sources.
Background Expanding sensitivity to HER2-targeted therapies remains a major clinical challenge in breast cancer, particularly in patients progressing after trastuzumab-based regimens or antibody–drug conjugates and in HER2-non-amplified tumors. While novel agents have expanded therapeutic options, intrinsic and acquired resistance mechanisms limit durable responses, underscoring the need for alternative strategies that overcome resistance. Here, we propose to redirect expanded effector lymphocytes, namely cytokine-induced killer (CIK) cells, with immuno-targeting agents, including HER2-targeted non-engineered monoclonal antibodies (mAbs), Fc-engineered antibodies, and bispecific antibodies (bsAbs). This represents a non-genetically modified adoptive cell therapy platform with intrinsic cytotoxicity and the potential for further enhancement through antibody-mediated immune redirection. Methods We generated CIK cells under serum-free, GMP-compliant conditions from patients with HER2 + breast cancer and healthy donors. We first evaluated their antitumor activity in vitro using real-time impedance-based assays against HER2-amplified and HER2-non-amplified breast cancer cell lines with low HER2 expression that were resistant to trastuzumab monotherapy. CIK cells were redirected using trastuzumab, Fc-engineered variants with enhanced CD16a binding, or a HER2×CD3 bispecific antibody. Functional persistence was assessed through tumor rechallenge assays. Antitumor efficacy and immune infiltration were evaluated in vivo using HER2-amplified patient-derived and HER2-non-amplified with low HER2 expression xenograft models. Results Antibody-redirected CIK cells effectively broadened sensitivity to HER2-targeted therapies in both HER2-amplified and HER2-non-amplified with low HER2 expression models. Fc-engineered and bispecific HER2 antibodies significantly enhanced CIK-mediated cytotoxicity against tumors unresponsive to trastuzumab alone and sustained effector function upon repeated tumor exposure. This resistance overcoming activity has been associated with the intrinsic cytotoxic capacity of CIKs, which increases when combined with antibodies, thereby leading to greater intratumor infiltration in vivo. Notably, Fc-optimized antibodies achieved superior tumor control in HER2-low models, where standard HER2-directed therapies are ineffective. Conclusions Antibody-redirected expanded effector lymphocytes represent a combinatorial immunotherapy approach that can broaden sensitivity to HER2-targeted therapies. This strategy offers logistical advantages and clinically translatable alternatives to other cell-based therapies and addresses a critical unmet need in HER2-amplified, HER2-non-amplified, and therapy-resistant breast cancer.
No takes yet. Share an insight, caveat, or question.
Ngo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: